Mural Oncology Primed For IL-2 Readouts Next Year

CEO Caroline Loew Outlined Firm’s Business Strategy

 
• By Jessica Merrill
  
dog waiting
Mural is waiting important data readouts on its IL-2 cytokine

More from Immuno-oncology

More from Anticancer